De nouveaux traitements pour le virus de l’hépatite C : stratégies pour parvenir à un accès universel

185 millions de personnes dans le monde sont infectées par le virus de l’hépatite C; 150 millions sont chroniquement infectées. Cette analyse tente de déterminer si les stratégies mises en œuvre par les compagnies pharmaceutiques pourraient assurer un meilleur accès au traitement. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

185 million people across the world are infected with HCV; 150 million are chronically infected. New treatments recently approved or soon to be authorized will offer a range of advantages compared with their predecessors: multigenotypic activity, fewer side effects, and higher cure rates, including for those in advanced stages of infection.

Although these new molecules will improve the quality of life of people with HCV and increase the number of people cured, their price will be out of reach of most of the people who need it. Gilead, like the other firms, is planning to apply different marketing strategies: “standard prices” in HICs, “tiered pricing” in MICs, and voluntary licencing in LICs.

This analysis, using epidemiological data specific to HCV, tries to determine whether the strategies employed by pharmaceutical companies would be good for access.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.